LianBio (LIANY)

OTCMKTS · Delayed Price · Currency is USD
0.0500
-0.0013 (-2.53%)
Aug 13, 2025, 3:25 PM EDT
-2.53%
Market Cap5.41M
Revenue (ttm)n/a
Net Income (ttm)-87.98M
Shares Out108.17M
EPS (ttm)-0.82
PE Ration/a
Forward PEn/a
Dividend0.38 (740.74%)
Ex-Dividend DateJul 15, 2025
Volume108
Average Volume180,893
Open0.0500
Previous Close0.0513
Day's Range0.0500 - 0.0500
52-Week Range0.0300 - 0.4394
Beta0.42
RSI20.03
Earnings DateAug 13, 2025

About LianBio

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatme... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 163
Stock Exchange OTCMKTS
Ticker Symbol LIANY
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.